Frontiers in antibiotics最新文献

{"title":"Assessment of antibiotic utilization patterns in an Indian Level-1 Trauma Center: a pilot study exploring days of antibiotic spectrum coverage and defined daily doses using WHO AWaRe classification trends.","authors":"M Nizam Ahmed, Arpan Kumar Thakur, Smriti Srivastava, Aparna Ningombam, Madhavi Kirti, Sushma Sagar, Keshav Goyal, Subodh Kumar, Ashish Bindra, Gyaninder Pal Singh, Navdeep Sokhal, Richa Aggarwal, Vijay Sharma, Samarth Mittal, Kamran Farooque, Purva Mathur","doi":"10.3389/frabi.2025.1578217","DOIUrl":"10.3389/frabi.2025.1578217","url":null,"abstract":"<p><strong>Background: </strong>Rising antimicrobial resistance (AMR) necessitates innovative metrics, such as days of antibiotic spectrum coverage (DASC), to optimize antibiotic stewardship. This study evaluated antibiotic use in an Indian trauma center using DASC, defined daily doses (DDD), and the World Health Organization (WHO) Access, Watch, Reserve (AWaRe) classification.</p><p><strong>Methods: </strong>This retrospective cohort study analyzed data from 1,812 adult inpatients (mean age: 35 years; 70% male; 80% with polytrauma) admitted to a 250-bed Level-1 Trauma Center at the All India Institute of Medical Sciences (AIIMS), India, from August to October 2022. We measured days of therapy (DOT), DDD, and DASC for 46 antibiotics across 12 pathogens [e.g., methicillin-susceptible <i>Staphylococcus aureus</i> (MSSA), carbapenem-resistant <i>Enterobacteriaceae</i>]. DASC scores were developed through expert consensus and local antibiogram data, and validated using Pearson's correlation with DOT (R = 0.43, p < 0.1) and DDD (R = 0.21). Differences in antibiotic usage between the ICU and ward were analyzed using a t-test in R software.</p><p><strong>Results: </strong>Total antibiotic consumption was 81,064.6 g (3,142 DDD/1,000 patient-days). The Watch group antibiotics dominated usage (37%, 16,018.6 g), resulting in a low Access-to-Watch ratio (0.47). ICU settings showed higher DDD values (326 vs. 193/1,000 patient-days, p < 0.05) and DASC/DOT ratios (mean: 3; 95% CI: 2.73-4.01). Piperacillin-tazobactam accounted for the largest share of the Watch category use (5,952.9 g). DASC values (mean 4401.5, 95% CI: 3592-5211.1) showed a moderate correlation with DOT (R = 0.43, p < 0.1), offering spectrum-specific insights.</p><p><strong>Conclusions: </strong>Excessive use of the Watch group antibiotics contributes significantly to AMR. However, DASC's novel, spectrum-focused approach offers a transformative tool for antibiotic stewardship, supporting targeted de-escalation and improved benchmarking. These findings underscore the urgent need for policy reforms to enforce adherence to the WHO AWaRe classification in Indian centers, potentially reducing AMR-related mortality (30% higher with resistant infections). Integrating DASC into global Antimicrobial stewardship (AMS) programs may redefine antibiotic prescribing practices and help mitigate the AMR crisis.</p>","PeriodicalId":73065,"journal":{"name":"Frontiers in antibiotics","volume":"4 ","pages":"1578217"},"PeriodicalIF":0.0,"publicationDate":"2025-07-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12304517/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144746349","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"National antibiotic consumption for human use in Chad (2017-2021): a descriptive cross-sectional study.","authors":"Zongo R Frank Edgard, Kadidjia Bakari Traoré, Colette Ngabéré, Martine Yoyammel, Abatcha Oumar Kadai, John Eyong Efobi, Mathieu Hota, Didi Lamireou, Badawi Haroun Mahamat, Hamit Mahamat Alio, Jacques L Tamuzi, Patrick D M C Katoto, Charles S Wiysonge, Blanche-Philomene Melanga Anya","doi":"10.3389/frabi.2025.1612557","DOIUrl":"10.3389/frabi.2025.1612557","url":null,"abstract":"<p><strong>Background: </strong>Antibiotic resistance (ABR) to commonly used antibiotics is significant in sub-Saharan Africa (SSA). In SSA, Chad has one of the highest antimicrobial resistance (AMR) rates. The link between ABR and antibiotic consumption (ABC) is well-established. However, no ABC-related studies have been conducted in Chad recently. The purpose of this study is to examine the trajectory of ABC in Chad from 2017 to 2021, using the World Health Organization's (WHO) Access, Watch, and Reserve (AWaRe) antibiotic classification.</p><p><strong>Methods: </strong>A descriptive retrospective study was conducted in N'Djamena, using antibiotic import and distribution data collected from the General Directorate of Pharmacy and four wholesale distributors of medicines. The defined daily doses (DDDs) and the mean relative change (MRC) were used to compute the results. Results were presented in terms of tables and graphs. The results were compared to the WHO's guidelines for ABC use via the AWaRe categorization.</p><p><strong>Results: </strong>Between 2017 and 2021, an average ABC of 2.5 doses per inhabitant per year was observed, peaking in 2020 at 5.3 doses per inhabitant. In terms of DDD, the ten most commonly consumed antibiotics during the time, in descending order, were amoxicillin, ampicillin, sulfamethoxazole/trimethoprim, doxycycline, ciprofloxacin, phenoxymethyl-penicillin, erythromycin, ceftriaxone, azithromycin, and gentamicin. However, the MRC analysis detected an increase in benzathine benzyl penicillin, benzylpenicillin, ampicillin, amoxicillin+clavulanic acid, flucloxacillin, ceftriaxone, cefixime, cefpodoxime and cefalexin, cotrimoxazole, ciprofloxacin, levofloxacin, norfloxacin, ofloxacin, and azithromycin. Controversially, amoxicillin, cefotaxime, doxycycline, erythromycin, and moxifloxacin had a lower MRC from 2017 to 2021. Although 90% of the ABC are from the \"Access\" group, the \"Watch\" group has increased over time.</p><p><strong>Conclusions: </strong>Our findings indicated a significant ABC in the Chadian population from 2017 to 2021, which may elucidate the country's elevated ABR. On average, 90% of ABC were categorized in the \"Access\" group, although utilization of the Watch group increased over time. This requires the prompt implementation of the monitoring system for ABC at all tiers in Chad.</p>","PeriodicalId":73065,"journal":{"name":"Frontiers in antibiotics","volume":"4 ","pages":"1612557"},"PeriodicalIF":0.0,"publicationDate":"2025-07-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12290472/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144735784","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Temporal dynamics of antimicrobial resistance gene abundances in chicken manure and anaerobic digestate.","authors":"Aleksandra Atanasova, Thomas Amon, Uwe Roesler, Anika Friese, Roswitha Merle, Tina Kabelitz","doi":"10.3389/frabi.2025.1612886","DOIUrl":"10.3389/frabi.2025.1612886","url":null,"abstract":"<p><strong>Introduction: </strong>Antimicrobial resistance (AMR) can spread in microorganisms through the transfer of antimicrobial resistance genes (ARGs). Livestock husbandry is one of the pathways for AMR emergence and transmission. Chicken manure contains valuable nutrients for agricultural field fertilization and can be used as input material for biogas production by anaerobic digestion (AD). However, usually, chicken manure also contains quite high levels of ARGs. In this study, we investigated the presence and temporal dynamics of ARGs against different antibiotic classes in chicken manure and anaerobic digestate as a source of AMR spread.</p><p><strong>Methods: </strong>To get an overview of the ARG profiles, we quantified the abundances of 374 ARGs by high-throughput (HT)-PCR. We studied eight selected ARGs (<i>tetA</i>, <i>tetX</i>, <i>sul1</i>, <i>sul2</i>, <i>lnuF</i>, <i>emrD</i>, <i>aadA</i>, and <i>tnpA</i>) using qPCR in chicken manure from different flocks and animal ages and in digestate from different AD time points.</p><p><strong>Results: </strong>Chicken manure showed higher amounts of ARGs compared to digestate, which was characterized by a higher ARG diversity. We observed that the effect of chicken age differed between the flocks. ARG abundances in digestate from different time points and different treatment conditions did not exhibit major changes.</p><p><strong>Conclusion: </strong>The flocks' variability had no relevant effect on ARG abundances in chicken manure, likely due to similar growth conditions. However, manure ARG content increased with the age of the chickens. In our experimental batch setup, AD was more effective in reducing AMR microorganisms than reducing ARGs. Further investigations on process optimization or the application of pre-treatment methods could enhance ARG reduction. Notably, pre-mixing chicken manure with material from a biogas plant prior to processing resulted in a lower ARG load compared to untreated chicken manure.</p>","PeriodicalId":73065,"journal":{"name":"Frontiers in antibiotics","volume":"4 ","pages":"1612886"},"PeriodicalIF":0.0,"publicationDate":"2025-06-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12245806/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144627890","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Synergistic effects of <i>Pandanus fascicularis</i> extracts and azithromycin: <i>in vitro</i> and <i>in silico</i> antimicrobial investigation against MDR clinical strains.","authors":"Mst Hajera Khatun, Md Rashedul Islam, Shikha Khatun, Amro Ahmed Zalah, Md Hadisur Rahman Rony, Mst Munira Khatun, Emad Essa A Wasili, Jaytirmoy Barmon, Saad Ahmed Sami, Abdulrahman Hadi Masmali, Ishtiaq Qadri","doi":"10.3389/frabi.2025.1552382","DOIUrl":"10.3389/frabi.2025.1552382","url":null,"abstract":"<p><strong>Background: </strong>Antibiotic-resistant bacteria are becoming a significant global concern. To combat the spread of resistance or reverse multidrug resistance, developing novel antimicrobials and/or resistance modulators is essential. This study aimed to evaluate the synergistic effects of the methanolic extract of <i>Pandanus fascicularis</i> fruits (MEPFF) in combination with azithromycin against multidrug-resistant bacteria.</p><p><strong>Methods: </strong>Phytochemical analysis along with the determination of total phenolic content (TPC), total flavonoid content (TFC), and total antioxidant capacity (TAC) of MEPFF, was performed using standard procedure. The extract's DPPH free radical scavenging activity was assessed to evaluate its potential antioxidant activity. The minimal inhibitory concentration (MIC) and minimal bactericidal concentration (MBC) of MEPFF against <i>Staphylococcus aureus</i>, <i>Bacillus cereus</i>, <i>Escherichia coli</i>, and <i>Pseudomonas aeruginosa</i> were determined, followed by an analysis of the synergistic effect with azithromycin, as well as the activity of azithromycin alone. Subsequently, the drug-likeness, antibacterial activity, and toxicological properties were analyzed using in silico tools.</p><p><strong>Results: </strong>The quantitative investigation found terpenoids, flavonoids, tannins, phenolics, saponins, cardiac glycosides, and alkaloids in MEPFF. The TFC, TPC, and TAC of MEPFF were found at 183 ± 9.54 mg QE, 248.33 ± 11.06 mg GAE, and 95.33 ± 8.33 mg AAE/gm extract. The extract showed significant antioxidant activity in the DPPH experiment, with an IC50 value of 12.13±0.53 µg/ml. Azithromycin and the extract together have far greater antibacterial action against all four bacterial strains. The minimal inhibitory concentration (MIC) is 3.67 ± 1.15 to 5.83 ± 0.76 mg/mL, while the minimum bactericidal concentration (MBC) is 4.33 ± 1.26 to 7.33 ± 1.04 mg/mL. In silico studies revealed that pandamarilactone-1, nonpandamarilactone-B, and thiamine had the best docking energy (-9.9, -8.9, and -8.5 kcal/mol), suggesting most active compounds against MPh-II protein.</p><p><strong>Conclusion: </strong>The extract enhances antibiotic therapy and suggests that the aforesaid synergistic drug-herb combinations may treat MDR bacterial infections.</p>","PeriodicalId":73065,"journal":{"name":"Frontiers in antibiotics","volume":"4 ","pages":"1552382"},"PeriodicalIF":0.0,"publicationDate":"2025-05-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12159755/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144287433","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Inclusion of patient-centered, non-microbiological endpoints and biomarkers in tuberculosis drug trials.","authors":"Andrew R DiNardo, Wilbert Sabiiti, Stephen H Gillespie, Sophia B Georghiou, Norbert Heinrich, Norbert Hittel, Sami Taghlabi, Danna Carrero Longlax, Mikashmi Kohli, Ursula Panzner, Collins Musia, Christoph Lange, Anca Vasiliu, Rob J W Arts, Anna M Mandalakas, Morten Ruhwald, Lieven J Stuyver, Reinout van Crevel","doi":"10.3389/frabi.2025.1570989","DOIUrl":"10.3389/frabi.2025.1570989","url":null,"abstract":"<p><p>Tuberculosis drug trials are primarily designed to identify antibiotic regimens with the strongest potency to kill <i>Mycobacterium tuberculosis</i>. However, microbiologic cure is not synonymous with improved health and recovery. Beyond antimicrobial efficacy, parameters such as morbidity and mortality related to lung function, cardiovascular health, and cancer should be prioritized. This narrative review emphasizes the critical need to emphasize clinical outcomes as much, if not more, than microbiological endpoints. We examine the underlying pathophysiological mechanisms and determinants of non-microbiological outcomes in tuberculosis, providing a synthesis of current knowledge. While there is growing evidence for some biomarkers to risk stratify TB patients for risk of all-cause mortality, relapse, or lung damage, no evidence was found on TB-associated cancer or cardiovascular disease. In addition to monitoring microbiologic outcomes, clinical trials and treatment cohorts need to capture patient-centered health dimensions more broadly. Finally, we highlight key research gaps and opportunities to evaluate non-microbiological biomarkers, aiming to improve patient monitoring and enable stratified approaches to tuberculosis management.</p>","PeriodicalId":73065,"journal":{"name":"Frontiers in antibiotics","volume":"4 ","pages":"1570989"},"PeriodicalIF":0.0,"publicationDate":"2025-05-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12140437/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144236026","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The burden, risk factors, and antimicrobial susceptibility pattern associated with extended-spectrum beta-lactamase-producing <i>E. coli</i> and <i>K. pneumoniae</i> carriage among neonates and their surroundings at a referral hospital in the Moshi municipality.","authors":"Happyness J Mshana, Dorottya Kovacs, Florida Muro, Ruth Zadoks, Katarina Oravcova, Louise Matthews, Blandina T Mmbaga","doi":"10.3389/frabi.2025.1556842","DOIUrl":"10.3389/frabi.2025.1556842","url":null,"abstract":"<p><strong>Introduction: </strong>Infections are a major driver of broad-spectrum antibiotic use. This wide use of antibiotics contributes to the emergence of antimicrobial resistance globally that poses a threat to human and animal health. Infections continue to be a major cause of death among pregnant women and neonates. Therefore, this study aimed to assess the burden of extended-spectrum beta-lactamase (ESBL)-producing <i>E. coli</i> and <i>K. pneumoniae</i> carriage among neonates and their surroundings admitted to a referral hospital in Northeast Tanzania.</p><p><strong>Methodology: </strong>The burden of ESBL-producing <i>E. coli</i> and <i>K. pneumoniae</i> in a neonatal ward was assessed by screening neonates' rectums, maternal and healthcare workers' hands, and neonatal cots. Isolates were cultured, identified, and tested for antimicrobial resistance, while generalized linear models identified risk factors for carriage.</p><p><strong>Results: </strong>A total of 437 neonates were screened for ESBL-producing <i>E. coli</i> and <i>K. pneumoniae</i>, with 235 (54%) being male. In addition, 77 maternal hand swabs, 118 neonatal cots, and 45 healthcare workers' hand swabs were collected. ESBL-producing <i>K. pneumoniae</i> was isolated from 198 neonates (45%), and <i>E. coli</i> from 96 (23%). Additionally, 5% of maternal hands and 22% of neonatal cots were contaminated with these resistant bacteria. Overall ampicillin resistance was frequent in ESBL-producing <i>E. coli</i> and ESBL <i>K. pneumoniae</i> neonatal colonization (n=261,100%), as was resistance to trimethoprim-sulfamethoxazole (<i>n</i> = 233,89%), gentamicin (<i>n</i> = 169, 66%), and tetracycline (<i>n</i> = 140,54%). Only three (1%) of the ESBL-producing <i>E. coli</i> and ESBL <i>K. pneumoniae</i> isolates were resistant to meropenem. Risk factors significantly associated with carriage of either ESBL-producing <i>E. coli</i> or <i>K. pneumoniae</i> were being born in an admission room [odds ratio (OR)=1.95, confidence interval (CI)=1.31-3.13, p=0.006] and delivery mode, with vaginal delivery associated with a reduced risk of carriage (OR=0.57, CI=0.35-0.92, p=0.023).</p><p><strong>Conclusion: </strong>The study reveals a high burden of ESBL-producing <i>K. pneumoniae</i> and <i>E. coli</i> in neonates and their environment, with frequent resistance to ampicillin and gentamicin. Hospital admission and cesarean delivery increase the risk of carriage, while vaginal delivery lowers it. Active screening upon admission and advanced diagnostic methods can help reduce transmission and guide effective antimicrobial treatment.</p>","PeriodicalId":73065,"journal":{"name":"Frontiers in antibiotics","volume":"4 ","pages":"1556842"},"PeriodicalIF":0.0,"publicationDate":"2025-05-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12134566/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144227849","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Quantification of bactericidal activity using the PATHFAST TB LAM Ag assay during the first 14 days of pulmonary tuberculosis treatment.","authors":"Ayumi Akinaga, Andreas H Diacon, Remous Ocloo, Atsushi Yanagida, Naofumi Yoda, Masanori Kawasaki, Yongge Liu","doi":"10.3389/frabi.2025.1574688","DOIUrl":"10.3389/frabi.2025.1574688","url":null,"abstract":"<p><strong>Background: </strong>Tuberculosis (TB) remains a global health challenge. Culture-free, rapid, and quantitative biomarkers to monitor treatment response are critical to accelerate development of better TB treatments. The PATHFAST TB LAM Ag assay (PATHFAST-LAM), a desktop chemiluminescent enzyme immunoassay that measures mycobacterial lipoarabinomannan (LAM) in sputum within 1 hour, is a promising candidate for this purpose. This study aimed to assess whether the PATHFAST-LAM can serve as a rapid, reliable biomarker for monitoring early treatment response in pulmonary TB.</p><p><strong>Methods: </strong>We conducted a retrospective longitudinal repository study using stored sputum samples from 14-day early bactericidal activity trials involving 75 pulmonary TB patients who received one of five different regimens. The results were compared with those from the TB LAM ELISA \"Otsuka\" (LAM-ELISA), which was previously shown to measure early bactericidal activity but takes more than 5 hours to obtain results, and conventional culture-based methods.</p><p><strong>Results: </strong>The LAM concentrations in both raw and decontaminated sputum showed strong correlations between the PATHFAST-LAM and the LAM-ELISA, with Spearman's correlation coefficients of 0.975 (95% CI: 0.971 - 0.979) and 0.987 (95% CI: 0.984 - 0.989), respectively. LAM concentrations in raw and decontaminated sputum by the PATHFAST-LAM were also highly correlated with a Spearman coefficient of 0.957 (95% CI: 0.950 - 0.964). Importantly, the LAM concentrations by the PATHFAST-LAM correlated with bacterial loads determined by culture-based methods in all five treatment arms (Spearman's coefficients: 0.723 - 0.947). Furthermore, the change in LAM levels over the treatment period mirrored the changes in bacterial load. Additionally, culture-based methods often result in missing data due to contamination: in our study, we observed a missing data rate of 9.6% (62/649) on quantifying CFU counts and 4.2% (27/649) on obtaining a valid MGIT TTD, while we obtained a valid LAM value with the PATHFAST-LAM (0/634 in raw samples and 0/637 in decontaminated samples).</p><p><strong>Conclusion: </strong>Our findings suggest that the PATHFAST-LAM can quantify bactericidal activity in the first 14 days of treatment with a quick turnaround time. The test's utility to monitor conversion from positive to negative and to predict relapse-free cure compared to culture-based methods should be determined in longer trials.</p>","PeriodicalId":73065,"journal":{"name":"Frontiers in antibiotics","volume":"4 ","pages":"1574688"},"PeriodicalIF":0.0,"publicationDate":"2025-05-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12120838/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144180488","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Vancomycin dosing in neonates: enhancing outcomes using population pharmacokinetics and simulation.","authors":"Sílvia M Illamola, Jiraganya Jj Bhongsatiern, Angela K Birnbaum, Shaun S Kumar, Joshua D Courter, David B Haslam, Karel Allegaert, David M Reith, Pankaj B Desai, Catherine M Sherwin","doi":"10.3389/frabi.2025.1568931","DOIUrl":"10.3389/frabi.2025.1568931","url":null,"abstract":"<p><strong>Introduction: </strong>Optimizing vancomycin dosing in neonates is a critical yet complex goal. Traditional trough concentration-based dosing strategies correlate poorly with therapeutic efficacy and often fail to account for the significant renal function variability and drug clearance in neonates. The 24-hour area under the concentration-time curve to minimum inhibitory concentration (AUC₂₄/MIC) ≥ 400 mg h/L has emerged as a superior pharmacodynamic target. Population pharmacokinetics (PopPK) models allow optimized dosing by incorporating neonatal-specific factors such as postmenstrual age (PMA), gestational age (GA), serum creatinine (SCr), and weight.</p><p><strong>Objective: </strong>To develop optimized vancomycin dosing regimens for neonates that achieve an 80% probability of target attainment (PTA) for an AUC₂₄/MIC ≥ 400 mg h/L across diverse clinical cohorts and simulated neonatal populations.</p><p><strong>Methods: </strong>Real-world data from three international centers (Belgium, New Zealand, USA), including 610 individuals and 2399 vancomycin concentrations, were used to externally evaluate a previously published PopPK model (NONMEM^®). Missing data, including body weight, were imputed using Amelia II version 1.7.3 for R, while Zelig for R integrated multiple imputed datasets. A virtual population of 10,000 neonates was independently generated using MATLAB to simulate clinical scenarios considering covariates such as PMA, GA, SCr, body weight, and imputed body length.</p><p><strong>Results: </strong>Simulations showed that PMA and SCr were key covariates that significantly improved PTA, particularly in preterm neonates. Preterm neonates achieved PTAs of 80% with daily doses of 30 or 40 mg/kg/day, while term neonates required 15 mg/kg every 8 hours or 20 mg/kg every 12 hours. The simulations demonstrated that these optimized dosing strategies achieved an 80% PTA for AUC₂₄/MIC ≥ 400 mg h/L in the virtual neonatal population. For neonates with PMA < 29 weeks and SCr > 0.6 mg/dL, including SCr as a covariate increased the likelihood of achieving the target from 65% to 87%.</p><p><strong>Conclusion: </strong>Incorporating developmental factors like PMA and SCr into vancomycin dosing strategies achieved robust and clinically relevant outcomes. The optimized regimens achieved an 80% PTA for the AUC₂₄/MIC target for preterm and term neonates. These findings offer a scalable framework for improving neonatal vancomycin pharmacotherapy across diverse populations and clinical settings.</p>","PeriodicalId":73065,"journal":{"name":"Frontiers in antibiotics","volume":"4 ","pages":"1568931"},"PeriodicalIF":0.0,"publicationDate":"2025-05-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12095254/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144129677","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Non-antibiotic therapies for multidrug-resistant gastrointestinal infections: an overview of the use of probiotics, natural compounds, and bacteriophages.","authors":"Manuela Oliveira, Áurea Madureira-Carvalho, Ricardo Jorge Dinis-Oliveira, Diana Dias da Silva","doi":"10.3389/frabi.2025.1554061","DOIUrl":"10.3389/frabi.2025.1554061","url":null,"abstract":"<p><p>The worldwide increasing frequency and severity of multidrug-resistant gastrointestinal (MDR-GI) infections not only raises awareness of the debilities of conventional antibiotic treatments but also highlights the demand for alternative interventions. One of these alternatives is probiotics, harmless bacteria that compete with pathogenic species, which have been considered beneficial due to their therapeutic potential since they strengthen the mucosal barrier and modulate the host immune response. Other natural compounds (e.g., polyphenols, flavonoids, and essential oils) present diverse antimicrobial mechanisms, which are promising alternatives to mitigate resistant pathogens. Finally, bacteriophages, viruses that target specific bacteria, constitute a precise approach in which MDR bacteria are lysed or disrupted by the biofilms formed during colonization without compromising the normal gut microbiome. Therefore, the present manuscript provides an integrated perspective on alternative non-antibiotic therapies to manage MDR-GI infections; for this purpose, it covers aspects such as their action mechanisms, current clinical applications, and the challenges that limit their broader application in clinical practice. The potential of combining these approaches or personalizing infection treatments adjusted to patients' microbiome profiles is also discussed, aiming to enhance efficacy and reduce resistance risks. Finally, the importance of continued research and development to optimize these alternatives is also debated, addressing aspects such as the need to surpass regulatory barriers and conducting large-scale clinical trials to establish the safety and efficacy of these non-antibiotic alternatives. This overview of the current knowledge contributes to the ongoing efforts to develop sustainable strategies to combat MDR-GI infections and reduce the global burden of antibiotic resistance.</p>","PeriodicalId":73065,"journal":{"name":"Frontiers in antibiotics","volume":"4 ","pages":"1554061"},"PeriodicalIF":0.0,"publicationDate":"2025-05-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12089134/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144112963","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Data transparency and reproducibility in health research: bridging the gap for early-career researchers.","authors":"Sanjib Bhakta, Jianping Xie, Federico Pea, Stephen H Gillespie","doi":"10.3389/frabi.2025.1562002","DOIUrl":"10.3389/frabi.2025.1562002","url":null,"abstract":"<p><p>In the evolving and interdisciplinary landscape of health and disease research, data transparency and reproducibility are increasingly recognised as essential for maintaining scientific integrity and trust. This article invites early-career researchers (ECRs) to engage critically with these principles while navigating the pressures of academic progression, publication demands, and career development. It examines the challenges ECRs face in maintaining reproducible practices and underscores the need for institutional support, inclusive training, and mentorship across all stages of the research career. Drawing on global initiatives and case studies, the article advocates for a more collaborative, diverse, and mentally healthy research culture. It also highlights alternative career pathways beyond academia, empowering ECRs to explore opportunities in industry, government, and non-governmental organisations. By integrating transparency with values such as team science, responsible metrics, and researcher wellbeing, this article reflects the ethos of the new generation of scientists and offers a timely call for systemic change and collective action to strengthen the future of research culture.</p>","PeriodicalId":73065,"journal":{"name":"Frontiers in antibiotics","volume":"4 ","pages":"1562002"},"PeriodicalIF":0.0,"publicationDate":"2025-04-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12070399/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144058408","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}